S100A4 and amyotrophic lateral sclerosis: Within the limitations of our analysis, which is mainly based on a small number of patients for each ALS subgroup, our results, showing S100A4 upregulation as a common hallmark in ALS fibroblasts, make S100A4 a potential candidate to be tested as a biomarker in the disease.